Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142740 · ClinicalTrials.gov registry record
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
A clinical trial of HIV Infection and Hepatitis B, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 337
- Enrollment target
- 4
- Study locations
NCT00142740: Completed study of HIV Infection and Hepatitis B, sponsored by University of North Carolina, Chapel Hill.
NCT00142740 is a study of HIV Infection and Hepatitis B that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 337 participants, above the 238-participant average among 73 other HIV Infection trials with a reported enrollment target (42% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142740, a study of HIV Infection and Hepatitis B, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 337 participants
- Enrollment target
- 4
- Study locations
Study Summary
This laboratory-based substudy of an effectiveness trial of two Hepatitis B vaccines in HIV-negative youths is being done to evaluate the genetic contribution to the individualized immune response.
Conditions Studied
Study Locations (4)
California
- Children's Hospital of Los Angeles - Los Angeles
- University of California at San Francisco - San Franciso
District of Columbia
- Children's Hospital National Medical Center - Washington D.C.
Florida
- University of Southern Florida College of Medicine - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-06 |
What the finished NCT00142740 record still lists
NCT00142740 is an observational study that tracks outcomes without assigning an intervention. The registered 337 participants enrollment target is mid-sized for trials with a published cap, above the 238-participant average among 73 other HIV Infection trials with a reported enrollment target (42% higher).
The record links to 2 conditions, with HIV Infection appearing as the primary indexed condition, and to 0 interventions.
NCT00142740 reports a single indexed study location in California, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT00142740 about?
NCT00142740 is a clinical study titled "Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025". This laboratory-based substudy of an effectiveness trial of two Hepatitis B vaccines in HIV-negative youths is being done to evaluate the genetic contribution to the individualized immune response.
What is the current status of trial NCT00142740?
This trial is currently completed. The enrollment target is 337 participants. The study started on 2005-10. Estimated completion is 2008-06.
What conditions does trial NCT00142740 study?
This clinical trial studies the following conditions: HIV Infection, Hepatitis B.
Who is sponsoring clinical trial NCT00142740?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00142740 being conducted?
This trial has 4 study locations across California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00142740's enrollment target sits among peer trials
337 13th of 73 higher than 61 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
MAPS PrEP Van Study
RECRUITING · Phase 4
-
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
RECRUITING · NA
-
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
RECRUITING · NA
-
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia